Conditions: Contraception Malposition of Intrauterine Contraceptive Device
Keywords: postpartum contraception intrauterine device intrauterine system mirena uterine involution
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 50
Healthy volunteers: yes

Brief summary:
This is a study of 50 postpartum women interested in having the Mirena® LNG-IUS placed for contraception. The Mirena® is an FDA approved intrauterine contraceptive device that provides contraception for 5 years with excellent effectiveness. Women enrolled in this study will only have the Mirena® placed at two-weeks postpartum (day 14-20 postpartum). The participants will be followed at 6-weeks and 6-months postpartum for study visits to evaluate for satisfaction, symptoms, expulsion, and perforation. The study will be completed at six-months postpartum, and participants will be able to keep their LNG-IUS following study completion.

Detailed description:

Arms:
arm 1: Enrolled women will have the LNG-IUS placed at two-weeks (14-20 days) postpartum

Interventions: intervention 1: Levonorgestrel Intrauterine System (LNG-IUS)
Intervention descriptions: intervention 1: The LNG-IUS will be inserted at two-weeks postpartum (day 14-20 postpartum) in all 50 women enrolled

Protocol document: